Dexmedetomidine + Sodium chloride 0.9%
Phase 3Completed 0 watching 0 views this week📈 Rising
74
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
ICU Delirium
Conditions
ICU Delirium
Trial Timeline
Jan 4, 2019 → Jun 29, 2021
NCT ID
NCT03477344About Dexmedetomidine + Sodium chloride 0.9%
Dexmedetomidine + Sodium chloride 0.9% is a phase 3 stage product being developed by Baxter for ICU Delirium. The current trial status is completed. This product is registered under clinical trial identifier NCT03477344. Target conditions include ICU Delirium.
Hype Score Breakdown
Clinical
27
Activity
18
Company
7
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03477344 | Phase 3 | Completed |
Competing Products
17 competing products in ICU Delirium
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Lemborexant 5 mg + Control (placebo) group | Eisai | Phase 2 | 52 |
| Suvorexant + Placebo | Merck | Phase 3 | 77 |
| Suvorexant 20 mg + Placebo | Merck | Phase 2 | 52 |
| Rivastigmine + Placebo | Novartis | Approved | 85 |
| Rivastigmine prevention of delirium | Novartis | Phase 3 | 77 |
| Rivastigmine transdermal patch + placebo patch | Novartis | Phase 3 | 77 |
| Rivastigmine Patch | Novartis | Approved | 85 |
| Dexmedetomidine + Placebo | Pfizer | Phase 3 | 76 |
| Parecoxib | Pfizer | Approved | 84 |
| Dexmedetomidine + Placebo | Pfizer | Phase 3 | 76 |
| Pregabalin | Pfizer | Phase 3 | 76 |
| Dexmedetomidine + Midazolam | Pfizer | Phase 3 | 76 |
| Propofol + Dexmedetomidine | Pfizer | Pre-clinical | 22 |
| Dexmedetomidine + Saline placebo | Pfizer | Phase 2/3 | 64 |
| Cyclopofol + Propofol | Haisco Pharmaceutical Group | Approved | 82 |
| Dexmedetomidine Hydrochloride Group | Brain Biotech | Approved | 77 |
| Dexmedetomidine sublingual film | BioXcel Therapeutics | Phase 2 | 44 |